Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Mineralys Therapeutics第四季度每股收益美元(0.61美元)超過預期(0.82美元)
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.82) by 25.61 percent. This is a 64.94 percent increase over losses of $(1.74) per share from the same period last year.
Mineralys Therapeutics(納斯達克股票代碼:MLYS)公佈的季度虧損爲每股0.61美元,比分析師共識估計的美元(0.82美元)高出25.61%。這比去年同期每股虧損1.74美元(1.74美元)增長了64.94%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。